Caribou Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the Annual Meeting of Stockholders held by Caribou Biosciences, Inc. on June 12, 2025. The filing details the voting outcomes for four specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results rather than financial performance data.
Material Changes and Voting Results
The following material actions were approved by shareholders:
- Director Elections: Two Class I directors were elected to serve until the 2028 annual meeting:
- Scott Braunstein, M.D.: 40,215,339 votes for; 1,952,924 votes withheld.
- Ran Zheng, M.S.: 30,392,577 votes for; 11,775,686 votes withheld.
- Accounting Firm Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (66,475,457 votes for).
- Reverse Stock Split Authorization: Shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-50, inclusive. The Board retains discretion to determine the specific ratio or abandon the amendment (59,816,707 votes for).
- Adjournment Authority: Shareholders approved the authority to adjourn the meeting if necessary to solicit further votes (47,879,959 votes for). Adjournment was not required as a quorum was established and all proposals passed.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure of the reverse stock split authorization.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and implementation date, as the Board has discretion to select a ratio between 1-for-5 and 1-for-50.
- Review the definitive proxy statement (Schedule 14A) filed on April 25, 2025, for detailed descriptions of the director nominees and proposals.
- Monitor subsequent filings for the official execution of the reverse stock split and any related capital structure changes.